DENTSPLY SIRONA (NASDAQ:XRAY) Issues Earnings Results, Misses Expectations By $0.01 EPS

DENTSPLY SIRONA (NASDAQ:XRAY) posted its quarterly earnings data on Tuesday. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01), FiscalAI reports. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

DENTSPLY SIRONA Stock Performance

Shares of XRAY traded up $0.17 during trading hours on Tuesday, hitting $11.37. The company’s stock had a trading volume of 9,456,053 shares, compared to its average volume of 4,456,731. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -3.79, a PEG ratio of 1.39 and a beta of 0.93. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The business has a 50 day simple moving average of $12.16 and a two-hundred day simple moving average of $12.03. DENTSPLY SIRONA has a 52-week low of $9.85 and a 52-week high of $17.18.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Mizuho raised their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Wells Fargo & Company raised their price objective on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. UBS Group decreased their price objective on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Bank of America upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Finally, Barrington Research lifted their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.91.

Insider Activity

In other DENTSPLY SIRONA news, Director James D. Forbes bought 5,000 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 9th. The stock was purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares of the company’s stock, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gregory T. Lucier bought 27,555 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 2nd. The stock was acquired at an average price of $14.24 per share, with a total value of $392,383.20. Following the purchase, the director directly owned 27,555 shares of the company’s stock, valued at approximately $392,383.20. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 70,000 shares of company stock valued at $956,437 in the last quarter. Corporate insiders own 0.52% of the company’s stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several hedge funds have recently bought and sold shares of the company. Daiwa Securities Group Inc. grew its stake in DENTSPLY SIRONA by 2.9% during the fourth quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after acquiring an additional 767 shares in the last quarter. Empowered Funds LLC grew its stake in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after acquiring an additional 1,320 shares in the last quarter. Wilmington Savings Fund Society FSB grew its stake in DENTSPLY SIRONA by 13.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier’s stock valued at $149,000 after acquiring an additional 1,500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in DENTSPLY SIRONA during the first quarter valued at approximately $26,000. Finally, Brevan Howard Capital Management LP grew its stake in DENTSPLY SIRONA by 9.9% during the second quarter. Brevan Howard Capital Management LP now owns 20,002 shares of the medical instruments supplier’s stock valued at $318,000 after acquiring an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.